CERBA-HEALTHCARE
18.11.2021 18:30:10 CET | Business Wire | Press release
According to the World Health Organisation , tuberculosis has been the world’s leading cause of infectious mortality for more than 20 years. Every year, 10 million people contract tuberculosis, and of these, an estimated one third of new cases are undetected. These 3 million cases therefore do not receive the treatment that they need and are extremely contagious. They account for most of the 10 million infections and 1.5 million victims of the disease the following year.
The main reason for this lack of detection is the lack of testing suitable for developing countries, where 80% of cases are found. Current tests require infrastructure and medical personnel, which are scarce in these countries and too expensive.
In order to face this challenge, the development of new Point-of-Care diagnostic methods is essential. Portable, easy to use, fast, cost effective and reliable, these systems extend the screening capacity in remote areas while maintaining the advantage of validation of the result and care for the patient by a clinical pathologist.
Based on a patent held by Université de Bourgogne and INRA, EpiLAB is developing an integrated POCT (point of care terminal) solution that aims to offer this accessible, medically rigorous solution in everyday practice.
According to Clément Dubois and Maurice Lubetzki, co-founders of EpiLAB , “By joining the Virtual Incubator of the Cerba HealthCare Group, the European leader in medical diagnosis already widely established in Africa, EpiLAB will be able to speed up the development of its test and its large-scale use . The collaboration with Cerba HealthCare will allow us to finalise a product as close as possible to the expectations and needs of the field in order to promote its adoption by healthcare professionals and optimise its integration into new patient treatment pathway ”.
“The partnership with EpiLAB marks a new stage in the success of our virtual incubator, our mechanism to support start-ups in open architecture that we created four years ago. The integration of Point of Care is a major issue in that it can improve healthcare pathways by making them increasingly relevant and effective for our patients. We also have several pilots underway in this field, both in Europe and in Africa ”, added Jérôme Sallette, Chief Scientific Officer of Cerba HealthCare .
About Cerba HealthCare
Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on 5 continents, the Group’s 12,000 employees sustain the transformation of medicine, driven by one deep conviction : to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health .
Additional information is available at www.cerbahealthcare.com
About EpiLAB
EpiLAB is an Ecole Polytechnique incubated company that develops a point-of-care tuberculosis diagnosis test helping health organizations fighting tuberculosis by bridging the diagnosis gap and downscaling contamination. The point-of-care screening kit meets the specifications defined by the World Health Organisation for such a test.
- Portable & easy to use: no infrastructure or medical staff is required
- Reliable: the basic detection threshold of the EpiLAB process is already close to the current standards associated with microscopic testing
- Quick: results are available in less than two hours and are sent to a cloud ensuring case traceability and case management
EpiLAB leverages a patented state of the art pairing microbiology and electrochemistry technology (n° WO/2018/178578, published on 04/10/18) which implies a tuberculosis biomarker electrochemical detection.
EpiLAB has won multiple innovation prizes, the 2020 Price of the Engineer of the Future and the start-up Challenge of Ecole Centrale. Additionally, the start-up partners with Hopital Bichat’s National Reference Center of mycobacteria (INSERM & APHP) and has 20 letters of interest from major tuberculosis international players, including FIND.
Additional information is available at www.epilab.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006090/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom